Entera Bio Ltd. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending June 29, 2020 was 2955.77% (a -3.77% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue increased by 65.28%
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 1813.98% (a 219.03% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2018 was 568.6% (a Infinity% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending June 29, 2020 was 2118.75% (a 30.46% increase compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue increased by Infinity% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
2118.75% 1624.1% 581.66% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of Entera Bio Ltd.

Most recent Selling, General and Administrative Expense of Revenueof ENTX including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of Entera Bio Ltd.

Entera Bio Ltd. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 2955.77% 3071.43%
2019 1494.12% 1788.33% 848.65% 0.0% 1813.98%
2018 185.8% 0.0% 0.0% 0.0% 568.6%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.